Ultragenyx Pharmaceutical Inc
NASDAQ:RARE
Ultragenyx Pharmaceutical Inc
NASDAQ:RARE
Price:
22.84
USD
1.02%
Market Closed
Market Cap:
$2.2B
Relative Value
The Relative Value of one
RARE
stock under the Base Case scenario is
37.1
USD.
Compared to the current market price of 22.84 USD,
Ultragenyx Pharmaceutical Inc
is
Undervalued by 38%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
RARE
Relative Value
Base Case
37.1
USD
Undervaluation 38%
Multiples Across Competitors
RARE Competitors Multiples
Ultragenyx Pharmaceutical Inc Competitors
Ultragenyx Pharmaceutical Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Ultragenyx Pharmaceutical Inc
NASDAQ:RARE
|
2.2B USD | 3.2 | -3.8 | -5.3 | -5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
401.3B USD | 6.6 | 95.9 | 15.7 | 21.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
202.4B USD | 5.5 | 26.2 | 15 | 15 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
184.4B USD | 6.3 | 21.7 | 13.5 | 16.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
126.8B USD | 10.6 | 32.1 | 24.3 | 25.3 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.6B USD | 5.7 | 18.1 | 13.6 | 15.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68.7B AUD | 3.2 | 34.9 | 11.5 | 14.5 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.1B EUR | 11.1 | 35.8 | 38.9 | 39.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
